AR034997A1 - Formula de vacuna contra las patogenias de los canidos, utilizacion de uno o de varios plasmidos, y kit de vacunacion - Google Patents
Formula de vacuna contra las patogenias de los canidos, utilizacion de uno o de varios plasmidos, y kit de vacunacionInfo
- Publication number
- AR034997A1 AR034997A1 ARP970103114A ARP970103114A AR034997A1 AR 034997 A1 AR034997 A1 AR 034997A1 AR P970103114 A ARP970103114 A AR P970103114A AR P970103114 A ARP970103114 A AR P970103114A AR 034997 A1 AR034997 A1 AR 034997A1
- Authority
- AR
- Argentina
- Prior art keywords
- valence
- canidos
- pathogenes
- vaccine formula
- various plasmids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Fórmula de vacuna contra las patogenias de los cánidos, que comprende al menos dos valencia de vacunas, cada una de las cuales comprende un plásmido integrante, de manera de expresar in vivo en las células huésped del cánido un gen de una valencia de patogenia canina, incluyendo una valencia del virus de la enfermedad de Carré CVD y una valencia del parvovirus canina CPV, comprendiendo los plásmidos para cada valencia uno o varios de los genes elegidos del grupo que comprende HA y F para el virus de la enfermedad de Carré y el gen VP2 para el parvovirus canino.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609401A FR2751227B1 (fr) | 1996-07-19 | 1996-07-19 | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034997A1 true AR034997A1 (es) | 2004-04-14 |
Family
ID=9494495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970103114A AR034997A1 (es) | 1996-07-19 | 1997-07-11 | Formula de vacuna contra las patogenias de los canidos, utilizacion de uno o de varios plasmidos, y kit de vacunacion |
Country Status (17)
Country | Link |
---|---|
US (2) | US6228846B1 (es) |
EP (1) | EP0954332B2 (es) |
JP (1) | JP2000515521A (es) |
KR (3) | KR20000067866A (es) |
AR (1) | AR034997A1 (es) |
AU (1) | AU733563B2 (es) |
BR (1) | BR9710509A (es) |
CA (1) | CA2260273C (es) |
CZ (1) | CZ300385B6 (es) |
DE (1) | DE69731309T3 (es) |
FR (1) | FR2751227B1 (es) |
NZ (1) | NZ333780A (es) |
PL (1) | PL190150B1 (es) |
RU (1) | RU2319504C2 (es) |
TW (1) | TW587942B (es) |
WO (1) | WO1998003199A1 (es) |
ZA (1) | ZA976284B (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2751227B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
US7294338B2 (en) * | 1996-07-19 | 2007-11-13 | Merial | Polynucleotide vaccine formula against canine pathologies, in particular respiratory and digestive pathologies |
CA2223029A1 (en) | 1997-02-12 | 1998-08-12 | Akzo Nobel Nv | Canine parvovirus dna vaccines |
EP0863151A1 (en) * | 1997-02-12 | 1998-09-09 | Akzo Nobel N.V. | "Canine parvovirus dna vaccines" |
US6368603B1 (en) * | 1997-03-05 | 2002-04-09 | Merial Limited | Lyme combination compositions and uses |
CA2375320C (en) * | 1999-06-10 | 2013-02-19 | Merial | Dna vaccines for pets or for animals used in sports |
FR2794648B1 (fr) * | 1999-06-10 | 2003-03-07 | Merial Sas | Vaccins adn pour animaux de compagnie et de sport |
US20040096462A1 (en) * | 2001-02-15 | 2004-05-20 | Rangarajan Pundi Narasimhan | Noval vaccine formulation consisting of dna vaccine and inactivated virus |
FR2823222B1 (fr) | 2001-04-06 | 2004-02-06 | Merial Sas | Vaccin contre le virus de la fievre du nil |
US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
AU2003299780A1 (en) * | 2002-12-19 | 2004-07-14 | Akzo Nobel Patent Department | Trivalent vaccine with maternal antibody transfer via the milk |
EP1606419A1 (en) | 2003-03-18 | 2005-12-21 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
WO2005021713A2 (en) | 2003-06-20 | 2005-03-10 | Protein Sciences Corporation | Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
ES2417019T3 (es) | 2003-11-13 | 2013-08-05 | University Of Georgia Research Foundation, Inc. | Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa |
CA2556911C (en) | 2004-02-19 | 2013-07-30 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
PL1881845T3 (pl) | 2005-04-25 | 2010-08-31 | Merial Ltd | Szczepionki przeciwko wirusowi Nipah |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
EP2186823A1 (en) | 2005-11-14 | 2010-05-19 | Merial Limited | Gene therapy for renal failure |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
US7767686B2 (en) * | 2006-03-03 | 2010-08-03 | Covidien Ag | Method of using adenosine receptor blockers during tissue ablation |
EP2019687B1 (en) | 2006-03-29 | 2014-03-19 | Merial Limited | Vaccine against streptococci |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
US20080274137A1 (en) * | 2007-05-02 | 2008-11-06 | Jean Christophe Francis Audonnet | DNA plasmids having improved expression and stability |
UA100692C2 (ru) | 2007-05-02 | 2013-01-25 | Мериал Лимитед | Днк-плазмиды, имеющие повышенную экспрессию и стабильность |
US8394384B2 (en) | 2008-11-28 | 2013-03-12 | Merial Limited | Recombinant avian influenza vaccine and uses thereof |
CA2757030C (en) | 2009-04-03 | 2019-01-15 | Merial Limited | Vectors comprising newcastle disease viruses and compositions thereof |
MX351643B (es) | 2009-12-28 | 2017-10-23 | Merial Ltd | Antigeno ndv recombinante y usos del mismo. |
US20130197612A1 (en) | 2010-02-26 | 2013-08-01 | Jack W. Lasersohn | Electromagnetic Radiation Therapy |
US9345759B2 (en) | 2010-03-12 | 2016-05-24 | Merial, Inc. | Bluetongue virus recombinant vaccines and uses thereof |
WO2012030720A1 (en) | 2010-08-31 | 2012-03-08 | Merial Limited | Newcastle disease virus vectored herpesvirus vaccines |
WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
EP2694678A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
US20140296248A1 (en) | 2011-04-04 | 2014-10-02 | Stichting het Nederlands Kanker Instiuut-Antoni van Leeuwenhoek ziekenhuis | Methods and compositions for predicting resistance to anticancer treatment |
WO2012145577A1 (en) | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
KR102007444B1 (ko) | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
US20120301479A1 (en) | 2011-05-27 | 2012-11-29 | Jean-Christophe Audonnet | Hendra virus recombinant compositions and uses thereof |
EP2714077B1 (en) | 2011-06-01 | 2018-02-28 | Merial, Inc. | Needle-free administration of prrsv vaccines |
JP6041361B2 (ja) | 2011-08-12 | 2016-12-07 | メリアル インコーポレイテッド | 生物学的製品、特にはワクチンの真空保存 |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
AU2013221479B2 (en) | 2012-02-14 | 2017-06-08 | Boehringer Ingelheim Animal Health USA Inc. | Rotavirus subunit vaccines and methods of making and use thereof |
JP6260972B2 (ja) | 2012-02-14 | 2018-01-17 | メリアル インコーポレイテッド | 狂犬病タンパク質及びox40タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン |
WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
NZ703297A (en) | 2012-06-13 | 2016-04-29 | Merial Ltd | Reassortant btv and ahsv vaccines |
US20140170180A1 (en) | 2012-12-17 | 2014-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5a, methods of use and vaccine |
US20140234354A1 (en) | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
US9556419B2 (en) | 2013-03-12 | 2017-01-31 | Merial Inc. | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof |
CA2915712A1 (en) * | 2013-08-21 | 2015-02-26 | Margit SCHNEE | Rabies vaccine |
WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
WO2015095811A2 (en) | 2013-12-20 | 2015-06-25 | The Board Institute Inc. | Combination therapy with neoantigen vaccine |
EP3215188A1 (en) | 2014-11-03 | 2017-09-13 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
EP3757211A1 (en) | 2014-12-19 | 2020-12-30 | The Broad Institute, Inc. | Methods for profiling the t-cell-receptor repertoire |
WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
KR20180010229A (ko) | 2015-05-20 | 2018-01-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 공유 신생항원 |
TWI750122B (zh) | 2015-06-09 | 2021-12-21 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
PL3313864T3 (pl) | 2015-06-23 | 2022-01-03 | Boehringer Ingelheim Animal Health USA Inc. | Rekombinowane wektory wirusowe zawierające drugorzędne białko prrsv oraz sposoby ich wytwarzania i zastosowania |
AU2016308630B2 (en) | 2015-08-20 | 2019-09-19 | Boehringer Ingelheim Animal Health USA Inc. | FCV recombinant vaccines and uses thereof |
MX2018004016A (es) | 2015-09-29 | 2018-11-29 | Merial Inc | Vacunas de particulas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos. |
MX2018006347A (es) | 2015-11-23 | 2019-02-20 | Merial Inc | Proteinas de fusion fmdv y e2 y usos de ellos. |
RU2626605C2 (ru) * | 2015-11-25 | 2017-07-28 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации |
TWI760322B (zh) | 2016-01-29 | 2022-04-11 | 美商百靈佳殷格翰動物保健美國有限公司 | 重組腺病毒載體裝載之fmdv疫苗及其用途 |
AU2017254477A1 (en) | 2016-04-18 | 2018-11-01 | Jennifer G. ABELIN | Improved HLA epitope prediction |
EP3574116A1 (en) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
CN108704128B (zh) * | 2018-05-15 | 2022-06-21 | 青岛农业大学 | 一种犬瘟热细小病毒二联亚单位疫苗 |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
RU2707544C1 (ru) * | 2018-12-28 | 2019-11-27 | Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) | Генетическая конструкция на основе оптимизированного гена консенсусного гликопротеина вируса бешенства для профилактики бешенства |
CN116735873B (zh) * | 2023-08-09 | 2023-10-31 | 北京纳百生物科技有限公司 | 特异性结合犬细小病毒vp2蛋白的单克隆抗体在检测试剂中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LU56248A1 (es) * | 1968-06-11 | 1970-01-15 | ||
JP3602530B2 (ja) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | 遺伝子操作したワクチン菌株 |
ES2348013T3 (es) * | 1994-01-27 | 2010-11-26 | University Of Massachusetts Medical Center | Inmunización por inoculación de una unidad de transcripción de adn. |
US6465438B1 (en) | 1996-04-19 | 2002-10-15 | Metin Colpan | Nucleic acid vaccination for parvoviral infections |
EP0954582A1 (en) | 1996-04-29 | 1999-11-10 | Andreas Prof. Zurbriggen | Polynucleotide vaccine against canine distemper |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2751227B1 (fr) * | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
CA2223029A1 (en) | 1997-02-12 | 1998-08-12 | Akzo Nobel Nv | Canine parvovirus dna vaccines |
IT1292422B1 (it) * | 1997-06-26 | 1999-02-08 | Agip Petroli | Reattore a bolle con draft tube e procedimento per la rigenerazione del catalizzatore in esso contenuto |
US6063385A (en) * | 1997-11-07 | 2000-05-16 | Wisconsin Alumni Research Foundation | DNA vaccine for parvovirus |
-
1996
- 1996-07-19 FR FR9609401A patent/FR2751227B1/fr not_active Expired - Lifetime
-
1997
- 1997-07-11 AR ARP970103114A patent/AR034997A1/es not_active Application Discontinuation
- 1997-07-15 BR BR9710509A patent/BR9710509A/pt not_active Application Discontinuation
- 1997-07-15 AU AU36993/97A patent/AU733563B2/en not_active Expired
- 1997-07-15 PL PL97331246A patent/PL190150B1/pl unknown
- 1997-07-15 CZ CZ0015899A patent/CZ300385B6/cs not_active IP Right Cessation
- 1997-07-15 NZ NZ333780A patent/NZ333780A/xx not_active IP Right Cessation
- 1997-07-15 JP JP10506630A patent/JP2000515521A/ja active Pending
- 1997-07-15 EP EP97933747.4A patent/EP0954332B2/fr not_active Expired - Lifetime
- 1997-07-15 WO PCT/FR1997/001316 patent/WO1998003199A1/fr not_active Application Discontinuation
- 1997-07-15 KR KR1019997000236A patent/KR20000067866A/ko active Application Filing
- 1997-07-15 KR KR1020057024166A patent/KR100620302B1/ko active IP Right Grant
- 1997-07-15 RU RU2002132833/13A patent/RU2319504C2/ru active
- 1997-07-15 DE DE69731309.3T patent/DE69731309T3/de not_active Expired - Lifetime
- 1997-07-15 KR KR1020057013739A patent/KR20050087885A/ko active Search and Examination
- 1997-07-15 CA CA2260273A patent/CA2260273C/en not_active Expired - Lifetime
- 1997-07-16 ZA ZA976284A patent/ZA976284B/xx unknown
- 1997-08-12 TW TW086111546A patent/TW587942B/zh not_active IP Right Cessation
-
1999
- 1999-01-15 US US09/232,477 patent/US6228846B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 US US09/784,982 patent/US6586412B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0954332B2 (fr) | 2014-12-31 |
BR9710509A (pt) | 1999-08-17 |
PL331246A1 (en) | 1999-07-05 |
CZ300385B6 (cs) | 2009-05-06 |
PL190150B1 (pl) | 2005-11-30 |
WO1998003199A1 (fr) | 1998-01-29 |
NZ333780A (en) | 2000-10-27 |
EP0954332B1 (fr) | 2004-10-20 |
DE69731309T2 (de) | 2005-11-17 |
CA2260273C (en) | 2010-12-21 |
US6586412B2 (en) | 2003-07-01 |
RU2319504C2 (ru) | 2008-03-20 |
KR20060013432A (ko) | 2006-02-09 |
EP0954332A1 (fr) | 1999-11-10 |
KR20000067866A (ko) | 2000-11-25 |
TW587942B (en) | 2004-05-21 |
CZ15899A3 (cs) | 1999-05-12 |
JP2000515521A (ja) | 2000-11-21 |
RU2002132833A (ru) | 2005-01-20 |
US6228846B1 (en) | 2001-05-08 |
FR2751227A1 (fr) | 1998-01-23 |
KR100620302B1 (ko) | 2006-09-06 |
DE69731309D1 (de) | 2004-11-25 |
FR2751227B1 (fr) | 1998-11-27 |
CA2260273A1 (en) | 1998-01-29 |
AU3699397A (en) | 1998-02-10 |
AU733563B2 (en) | 2001-05-17 |
KR20050087885A (ko) | 2005-08-31 |
ZA976284B (en) | 1999-01-19 |
DE69731309T3 (de) | 2015-06-03 |
US20010009959A1 (en) | 2001-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034997A1 (es) | Formula de vacuna contra las patogenias de los canidos, utilizacion de uno o de varios plasmidos, y kit de vacunacion | |
AR007864A1 (es) | Formula de vacuna porcina, su utilizacion y kit de vacunacion que la contiene. | |
AR013063A1 (es) | Formula de vacuna aviaria, su utilizacion y kit de vacunacion | |
AR007861A1 (es) | Formula de vacuna para gatos, su utilizacion y kit de vacunacion | |
AR007862A1 (es) | Vacuna bovina, su uso y kit de vacunación que la contiene. | |
AR059828A2 (es) | Formula de vacuna para equidos, su utilizacion y kit de vacunacion | |
Singh et al. | Re-emerging fowlpox: evaluation of isolates from vaccinated flocks | |
ES2399845T3 (es) | Herpesvirus de pavo vectorial recombinante que contiene genes de la influencia aviar | |
Wang et al. | Efficacy of DNA vaccines against infectious bursal disease virus in chickens enhanced by coadministration with CpG oligodeoxynucleotide | |
AR005930A1 (es) | Genes hiv sinteticos, composiciones de vacunas relacionadas y metodo para aumentar la expresion de adn | |
CO5360638A1 (es) | Un cepillo de dientes con cerdas individualmente embebidas | |
WO1998003660A9 (fr) | Formule de vaccin polynucleotidique felin | |
ES2143507T3 (es) | Vacunas contra la enfermedad de aujeszky y de otras enfermedades animales que contienen mutantes del virus de la pseudorrabia. | |
RU2006140984A (ru) | Вакцина против пародонтоза | |
CO6290703A2 (es) | Vacunas que contienen variantes genericas de parvovirus canino | |
ES2283105T3 (es) | Vacunas en el adn con polimeros de acido acrilico o metacrilico o de ema (r) para los caballos. | |
Zheng et al. | Study on the distribution and expression of a DNA vaccine against lymphocystis disease virus in Japanese flounder (Paralichthys olivaceus) | |
Gall-Reculé et al. | Importance of a prime–boost DNA/protein vaccination to protect chickens against low-pathogenic H7 avian influenza infection | |
Singh et al. | Construction and characterization of a fowlpox virus field isolate whose genome lacks reticuloendotheliosis provirus nucleotide sequences | |
BR0102322A (pt) | Vìrus de uma cepa de vìrus de doença bursal infecciosa, vacina contra doença bursal infecciosa, métodos para a preparação do vìrus, e da vacina, e, uso do vìrus | |
CU23245A1 (es) | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS | |
AR122653A1 (es) | Vectores de hvt recombinantes que expresan hemaglutinina de influenza y composiciones inmunogénicas, su producción y usos | |
AR031599A1 (es) | Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz | |
ECSP972183A (es) | Formula de vacuna polinucleotidica aviaria | |
Ghaemi et al. | Simultaneous formulation of chemical and genetic adjuvants could result in finding an efficient H5 influenza DNA vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |